Abstract
In the last two decades, the only proven pathogenetic treatment of CKD was blockade of the renin-angiotensin system (RAAS) - with ACE inhibitors and angiotensin-receptor blockers (ARBs). Advances came with the advent of SGLT2 inhibitors, which not only improved glycemic control in diabetics, but also demonstrated proven renoprotective and cardiovascular benefits independent of glycemic control. Key clinical studies such as DAPA-CKD and EMPAKIDNEY, FIDELIO-DKD, FIGARO-DKD proved their cardioprotection and nephroprotection. The aim of the present analysis is to review and compare the groups of drugs with proven renoprotective effects.
Key words: chronic kidney disease, perspectives, treatment

Download full text as PDF file